Gonadotrophin-releasing hormone antagonists for assisted reproductive technology
- 11 May 2011
- reference entry
- Published by Wiley
- No. 5,p. CD001750
Abstract
Background Gonadotrophin‐releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo‐estrogenic side‐effects, flare‐up, or long down‐regulation period associated with agonists. The antagonists directly and rapidly inhibit gonadotropin release within several hours through competitive binding to pituitary GnRH receptors. This property allows their use at any time during the follicular phase. Several different regimes have been described including multiple‐dose fixed (0.25 mg daily from day six to seven of stimulation), multiple‐dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single‐dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill. Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS). Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens. This is an update of a Cochrane review first published in 2001, and previously updated in 2006. Objectives To evaluate the effectiveness and safety of gonadotrophin‐releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycle Search methods We performed electronic searches of major databases, for example Cochrane Menstrual Disorders and Subfertility Group Specialised Register, CENTRAL, MEDLINE, EMBASE (from 1987 to April 2010); and handsearched bibliographies of relevant publications and reviews, and abstracts of major scientific meetings, for example the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM). Selection criteria Two review authors independently screened the relevant citations for randomised controlled trials (RCTs) comparing different agonist versus antagonist protocols in women undergoing IVF or ICSI. Data collection and analysis Two review authors independently assessed trial risk of bias and extracted data. If relevant data were missing or unclear, the authors were contacted for clarification. Main results Forty‐five RCTs (n = 7511) comparing the antagonist to the long agonist protocols fulfilled the inclusion criteria. There was no evidence of a statistically significant difference in rates of live‐births (9 RCTs; odds ratio (OR) 0.86, 95% CI 0.69 to 1.08). There was a statistically significant lower incidence of OHSS in the GnRH antagonist group (29 RCTs; OR 0.43, 95% CI 0.33 to 0.57). Authors' conclusions The use of antagonist compared with long GnRH agonist protocols was associated with a large reduction in OHSS and there was no evidence of a difference in live‐birth rates.Keywords
This publication has 79 references indexed in Scilit:
- Characteristics of Progesterone Changes in Women with Subtle Progesterone Rise in Recombinant Follicle-Stimulating Hormone and Gonadotropin-Releasing Hormone Antagonist CycleGynecologic and Obstetric Investigation, 2010
- IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized studyJournal of Assisted Reproduction and Genetics, 2009
- Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols forin vitrofertilisation and embryo transferGynecological Endocrinology, 2009
- Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized studyJournal of Assisted Reproduction and Genetics, 2008
- Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?Fertility and Sterility, 2008
- The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled studyFertility and Sterility, 2008
- Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipientsGynecological Endocrinology, 2008
- A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermiaFertility and Sterility, 2005
- A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocolFertility and Sterility, 2004
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?The Lancet, 1998